Gestational Diabetes Market Size, Share, Growth & Forecast

Gestational Diabetes Market Size:

Gestational Diabetes Market size is estimated to reach over USD 19,811.32 Million by 2032 from a value of USD 9,870.25 Million in 2024 and is projected to grow by USD 10,592.57 Million in 2025, growing at a CAGR of 9.1% from 2025 to 2032.

 Gestational diabetes mellitus (GDM) is a condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy. If left unmanaged, GDM can lead to serious complications for both the mother (preeclampsia, future Type 2 diabetes) and the infant (macrosomia, hypoglycemia). The market for GDM includes diagnostic screening kits, continuous glucose monitors (CGM), insulin delivery systems, and specialized nutritional therapy.

Gestational Diabetes Market Overview

Gestational diabetes is a condition characterized by elevated blood glucose levels during pregnancy, typically affecting women with no prior history of diabetes. It occurs due to hormonal changes that impair insulin function, requiring effective diagnosis, monitoring, and management. Products in this market include diagnostic tools, insulin delivery devices, and glucose monitoring systems. These products offer features such as accurate glucose measurement, real-time data tracking, and enhanced patient convenience. Advanced technologies also support remote monitoring and personalized treatment plans.

• Diagnostic Standard: The Oral Glucose Tolerance Test (OGTT) remains the largest diagnostic segment, accounting for 45% of the market.

• Growth in CGM: Continuous Glucose Monitors are the fastest-growing technology segment as expectant mothers seek real-time, non-invasive monitoring.

• Shift to Home Care: There is a definitive trend toward self-management, with "Smart" apps and telehealth connecting mothers directly to obstetric teams.

Gestational Diabetes Market Drivers

The adoption of self-monitoring devices, including continuous glucose monitoring (CGM) systems, has significantly improved the management of gestational diabetes. These devices empower pregnant women to track their glucose levels in real time, ensuring better glycemic control and reducing risks for both mother and child. For example, CGM systems provide alerts for abnormal glucose levels, enabling timely intervention and improved health outcomes.Rising obesity rates and advanced maternal age are the primary drivers of this condition's increased prevalence.

• Demographic Shifts: More women are having children later in life (35+), which is a key risk factor for the Gestational Diabetes Market.

• Global Obesity Epidemic: Increasing BMI among the reproductive-age population is leading to higher insulin resistance during pregnancy.

• Awareness Programs: Government initiatives in emerging economies are mandating universal GDM screening, significantly increasing the volume of diagnostic tests performed.

Gestational Diabetes Market Restraints

The costs associated with advanced diagnostic tools and monitoring devices limit their accessibility, particularly in low-income regions. These expenses include the purchase price, maintenance, and periodic sensor replacement for devices like CGM systems. For instance, continuous glucose monitors require frequent sensor updates, which can be expensive and are often not covered by insurance.Healthcare access and psychological barriers pose challenges to market growth:

• Cost of Technology: High-end CGMs and insulin pumps remain prohibitively expensive for patients in low-to-middle-income countries.

• Diagnostic Hurdles: Variability in GDM diagnostic criteria between different international health organizations can lead to under-diagnosis or over-diagnosis.

• Patient Compliance: Stricter dietary requirements and frequent monitoring often lead to "burnout" and reduced adherence to treatment plans.

• Regulatory Compliance: New insulin analogs and monitoring devices face lengthy clinical trials to ensure safety for both mother and fetus.

Gestational Diabetes Market Opportunities

Artificial intelligence (AI) is expected to revolutionize gestational diabetes management by providing personalized treatment plans based on individual patient data. AI algorithms will analyze glucose patterns, dietary habits, and physical activity levels to recommend tailored interventions. For example, AI-powered applications could suggest specific dietary changes to maintain optimal glucose levels during pregnancy.Digital therapeutics and personalized nutrition offer vast untapped potential:

• AI-Driven Predictive Analytics: Using machine learning to identify high-risk mothers in the first trimester before symptoms manifest.

• Telehealth Bundles: Offering integrated packages that include devices, virtual coaching, and digital food logs for a monthly subscription fee.

• Non-invasive Monitoring: Developing "smart patches" or saliva-based glucose tests to replace traditional finger-prick methods.

• Postpartum Care: Expanding the service model to monitor women for Type 2 diabetes for several years following delivery.

Gestational Diabetes Market Key Players

• Novo Nordisk A/S (Denmark)

• Sanofi S.A. (France)

• Bristol-Myers Squibb (United States)

• Eli Lilly and Co. (United States)

• Bayer AG (Germany)

• GlaxoSmithKline plc (United Kingdom)

• Abbott Laboratories (United States)

• Merck & Co., Inc. (United States)

• Johnson & Johnson (United States)

• Medtronic PLC (Ireland)

 Gestational Diabetes Market Segmentation

By Type         

• Type A1

• Type A2

• Others

By Treatment Type  

• Insulin Therapy

• Oral Anti-Diabetic Drugs

• Non-Pharmacological Treatment

By Administration    

• Oral

• Intravenous

• Others

By Diagnosis 

• Oral Glucose Tolerance Test (OGTT)

• Fasting Blood Sugar Test

• Random Blood Sugar Test

• Hemoglobin A1C Test

Gestational Diabetes Market Regional Analysis

• North America currently holds the largest revenue share (34%), driven by high healthcare expenditure and the early adoption of CGM technology.

• Asia-Pacific is expected to grow at the fastest CAGR through 2032 due to a high genetic predisposition to diabetes in South Asian populations and improving access to prenatal care in rural China and India.

Gestational Diabetes Market Recent Developments

In early 2026, major medical associations released updated "Standards of Care" that emphasize medical nutrition therapy as the first line of defense, potentially boosting the market for specialized prenatal diet apps. Additionally, a new wave of "smart insulin pens" has been launched, which automatically logs doses and syncs with maternal health apps to prevent under-dosing or over-dosing.

About Us:

At Consegic Business Intelligence Pvt. Ltd., we empower businesses with actionable insights and innovative market intelligence solutions. Our tailored research and data-driven strategies help organizations navigate complex industry landscapes and makeconfident decisions.

Specializing in market research, consulting, and competitive analysis, we deliverprecise and holistic insights across global and regional markets. Our client-focusedapproach ensures customized solutions that drive growth and foster informeddecision-making.

Contact Us:Consegic Business intelligence Pvt Ltd.

Contact No: +1-252-552-1404

Email: sales@consegicbusinessintelligence.com